Methylphenidate dose optimization for ADHD treatment: review of safety, efficacy, and clinical necessity

Michael Huss,1 Praveen Duhan,2 Preetam Gandhi,3 Chien-Wei Chen,4 Carsten Spannhuth,3 Vinod Kumar5 1Child and Adolescent Psychiatry, University Medicine, Mainz, Germany; 2Global Medical Affairs, Novartis Healthcare Pvt. Ltd., Hyderabad, India; 3Development Franchise, Established Medicine Neuroscienc...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Huss M, Duhan P, Gandhi P, Chen CW, Spannhuth CW, Kumar V
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2017
Materias:	Methylphenidate Dose optimization Attention-deficit/hyperactivity disorder ADHD Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429
Acceso en línea:	https://doaj.org/article/c6b9b283f2d5497aa7c00386ee560f18
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:c6b9b283f2d5497aa7c00386ee560f18
record_format	dspace
spelling	oai:doaj.org-article:c6b9b283f2d5497aa7c00386ee560f182021-12-02T01:40:11ZMethylphenidate dose optimization for ADHD treatment: review of safety, efficacy, and clinical necessity1178-2021https://doaj.org/article/c6b9b283f2d5497aa7c00386ee560f182017-07-01T00:00:00Zhttps://www.dovepress.com/methylphenidate-dose-optimization-for-adhd-treatment-review-of-safety--peer-reviewed-article-NDThttps://doaj.org/toc/1178-2021Michael Huss,1 Praveen Duhan,2 Preetam Gandhi,3 Chien-Wei Chen,4 Carsten Spannhuth,3 Vinod Kumar5 1Child and Adolescent Psychiatry, University Medicine, Mainz, Germany; 2Global Medical Affairs, Novartis Healthcare Pvt. Ltd., Hyderabad, India; 3Development Franchise, Established Medicine Neuroscience, Novartis Pharma AG, Basel, Switzerland; 4Biostatistics Cardio-Metabolic & Established Medicine, Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA; 5Established Medicines, Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA Abstract: Attention-deficit/hyperactivity disorder (ADHD) is a chronic psychiatric disorder characterized by hyperactivity and/or inattention and is often associated with a substantial impact on psychosocial functioning. Methylphenidate (MPH), a central nervous system stimulant, is commonly used for pharmacological treatment of adults and children with ADHD. Current practice guidelines recommend optimizing MPH dosage to individual patient needs; however, the clinical benefits of individual dose optimization compared with fixed-dose regimens remain unclear. Here we review the available literature on MPH dose optimization from clinical trials and real-world experience on ADHD management. In addition, we report safety and efficacy data from the largest MPH modified-release long-acting Phase III clinical trial conducted to examine benefits of dose optimization in adults with ADHD. Overall, MPH is an effective ADHD treatment with a good safety profile; data suggest that dose optimization may enhance the safety and efficacy of treatment. Further research is required to establish the extent to which short-term clinical benefits of MPH dose optimization translate into improved long-term outcomes for patients with ADHD. Keywords: methylphenidate, dose optimization, attention-deficit/hyperactivity disorder, ADHDHuss MDuhan PGandhi PChen CWSpannhuth CWKumar VDove Medical PressarticleMethylphenidateDose optimizationAttention-deficit/hyperactivity disorderADHDNeurosciences. Biological psychiatry. NeuropsychiatryRC321-571Neurology. Diseases of the nervous systemRC346-429ENNeuropsychiatric Disease and Treatment, Vol Volume 13, Pp 1741-1751 (2017)
institution	DOAJ
collection	DOAJ
language	EN
topic	Methylphenidate Dose optimization Attention-deficit/hyperactivity disorder ADHD Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429
spellingShingle	Methylphenidate Dose optimization Attention-deficit/hyperactivity disorder ADHD Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429 Huss M Duhan P Gandhi P Chen CW Spannhuth CW Kumar V Methylphenidate dose optimization for ADHD treatment: review of safety, efficacy, and clinical necessity
description	Michael Huss,1 Praveen Duhan,2 Preetam Gandhi,3 Chien-Wei Chen,4 Carsten Spannhuth,3 Vinod Kumar5 1Child and Adolescent Psychiatry, University Medicine, Mainz, Germany; 2Global Medical Affairs, Novartis Healthcare Pvt. Ltd., Hyderabad, India; 3Development Franchise, Established Medicine Neuroscience, Novartis Pharma AG, Basel, Switzerland; 4Biostatistics Cardio-Metabolic & Established Medicine, Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA; 5Established Medicines, Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA Abstract: Attention-deficit/hyperactivity disorder (ADHD) is a chronic psychiatric disorder characterized by hyperactivity and/or inattention and is often associated with a substantial impact on psychosocial functioning. Methylphenidate (MPH), a central nervous system stimulant, is commonly used for pharmacological treatment of adults and children with ADHD. Current practice guidelines recommend optimizing MPH dosage to individual patient needs; however, the clinical benefits of individual dose optimization compared with fixed-dose regimens remain unclear. Here we review the available literature on MPH dose optimization from clinical trials and real-world experience on ADHD management. In addition, we report safety and efficacy data from the largest MPH modified-release long-acting Phase III clinical trial conducted to examine benefits of dose optimization in adults with ADHD. Overall, MPH is an effective ADHD treatment with a good safety profile; data suggest that dose optimization may enhance the safety and efficacy of treatment. Further research is required to establish the extent to which short-term clinical benefits of MPH dose optimization translate into improved long-term outcomes for patients with ADHD. Keywords: methylphenidate, dose optimization, attention-deficit/hyperactivity disorder, ADHD
format	article
author	Huss M Duhan P Gandhi P Chen CW Spannhuth CW Kumar V
author_facet	Huss M Duhan P Gandhi P Chen CW Spannhuth CW Kumar V
author_sort	Huss M
title	Methylphenidate dose optimization for ADHD treatment: review of safety, efficacy, and clinical necessity
title_short	Methylphenidate dose optimization for ADHD treatment: review of safety, efficacy, and clinical necessity
title_full	Methylphenidate dose optimization for ADHD treatment: review of safety, efficacy, and clinical necessity
title_fullStr	Methylphenidate dose optimization for ADHD treatment: review of safety, efficacy, and clinical necessity
title_full_unstemmed	Methylphenidate dose optimization for ADHD treatment: review of safety, efficacy, and clinical necessity
title_sort	methylphenidate dose optimization for adhd treatment: review of safety, efficacy, and clinical necessity
publisher	Dove Medical Press
publishDate	2017
url	https://doaj.org/article/c6b9b283f2d5497aa7c00386ee560f18
work_keys_str_mv	AT hussm methylphenidatedoseoptimizationforadhdtreatmentreviewofsafetyefficacyandclinicalnecessity AT duhanp methylphenidatedoseoptimizationforadhdtreatmentreviewofsafetyefficacyandclinicalnecessity AT gandhip methylphenidatedoseoptimizationforadhdtreatmentreviewofsafetyefficacyandclinicalnecessity AT chencw methylphenidatedoseoptimizationforadhdtreatmentreviewofsafetyefficacyandclinicalnecessity AT spannhuthcw methylphenidatedoseoptimizationforadhdtreatmentreviewofsafetyefficacyandclinicalnecessity AT kumarv methylphenidatedoseoptimizationforadhdtreatmentreviewofsafetyefficacyandclinicalnecessity
_version_	1718402984339046400

Methylphenidate dose optimization for ADHD treatment: review of safety, efficacy, and clinical necessity

Ejemplares similares